aprepitant and Lymphoma--T-Cell--Cutaneous

aprepitant has been researched along with Lymphoma--T-Cell--Cutaneous* in 9 studies

Reviews

1 review(s) available for aprepitant and Lymphoma--T-Cell--Cutaneous

Article	Year
Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature. BMC cancer, 2017, 03-16, Volume: 17, Issue:1 Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global mediator.. We report a series of four patients, diagnosed with cutaneous T-cell lymphoma, who experienced full body pruritus recalcitrant to standard therapies. All patients experienced rapid symptom improvement (within days) following aprepitant treatment.. Aprepitant has been shown in small studies to be efficacious for treating chronic and malignancy-associated pruritus. Prior studies have shown no change in clinical efficacy of chemotherapeutics with concurrent aprepitant administration. These cases further demonstrate that aprepitant can be considered as a therapeutic option in malignancy-associated pruritus and further support the need for larger clinical trials. Topics: Adult; Aged; Aprepitant; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Protein Binding; Pruritus; Substance P	2017

Article

Year

Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.

BMC cancer, 2017, 03-16, Volume: 17, Issue:1

Aprepitant is an FDA-approved medication for chemotherapy-induced nausea and vomiting. It blocks substance P binding to neurokinin-1; substance P has been implicated in itch pathways both as a local and global mediator.. We report a series of four patients, diagnosed with cutaneous T-cell lymphoma, who experienced full body pruritus recalcitrant to standard therapies. All patients experienced rapid symptom improvement (within days) following aprepitant treatment.. Aprepitant has been shown in small studies to be efficacious for treating chronic and malignancy-associated pruritus. Prior studies have shown no change in clinical efficacy of chemotherapeutics with concurrent aprepitant administration. These cases further demonstrate that aprepitant can be considered as a therapeutic option in malignancy-associated pruritus and further support the need for larger clinical trials.

Topics: Adult; Aged; Aprepitant; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Protein Binding; Pruritus; Substance P

2017

Other Studies

8 other study(ies) available for aprepitant and Lymphoma--T-Cell--Cutaneous

Article	Year
Antipruritic vs. Antitumour Action of Aprepitant: A Question of Dose. Acta dermato-venereologica, 2019, May-01, Volume: 99, Issue:6 Topics: Antineoplastic Agents; Antipruritics; Aprepitant; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lymphoma, T-Cell, Cutaneous; Neurokinin-1 Receptor Antagonists; Pruritus; Skin Neoplasms; Treatment Outcome	2019
Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas. The British journal of dermatology, 2018, Volume: 178, Issue:4 Topics: Antipruritics; Aprepitant; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lymphoma, T-Cell, Cutaneous; Pruritus; Retrospective Studies; Skin Neoplasms; Treatment Outcome	2018
Effects of neuroimmune axis modulation by aprepitant on antipruritic and global disease severity in patients with cutaneous T-cell lymphoma. The British journal of dermatology, 2018, Volume: 178, Issue:5 Topics: Antipruritics; Aprepitant; Humans; Lymphoma, T-Cell, Cutaneous; Pruritus; Skin Neoplasms	2018
Aprepitant did not modify global disease activity in cutaneous T-cell lymphomas. The British journal of dermatology, 2018, Volume: 178, Issue:5 Topics: Antipruritics; Aprepitant; Humans; Lymphoma, T-Cell, Cutaneous; Skin Neoplasms	2018
Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma. Actas dermo-sifiliograficas, 2014, Volume: 105, Issue:7 Topics: Aprepitant; Female; Humans; Lymphoma, T-Cell, Cutaneous; Middle Aged; Morpholines; Pruritus; Skin Neoplasms	2014
[Role of aprepitant in the management of pruritus in a patient with cutaneous T-cell lymphoma]. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2014, Apr-01, Volume: 38, Issue:2 - Topics: Aged; Aprepitant; Humans; Lymphoma, T-Cell, Cutaneous; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Pruritus; Skin Neoplasms	2014
Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology, 2012, Volume: 67, Issue:5 Topics: Aged; Antipruritics; Aprepitant; Drug Therapy, Combination; Female; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Morpholines; Neurokinin-1 Receptor Antagonists; Ondansetron; Pain Measurement; Recombinant Proteins; Substance P	2012
Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. The British journal of dermatology, 2011, Volume: 164, Issue:3 Topics: Administration, Oral; Aged; Antipruritics; Aprepitant; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Prospective Studies; Pruritus; Quality of Life; Surveys and Questionnaires	2011